| Identification | Back Directory | [Name]
Notoginsenoside R1 | [CAS]
80418-24-2 | [Synonyms]
NOTOGINSENOSIDE
Sanchinoside R1
Notoginsenoside Fb
NOTOGINSENOSIDE R1
Sanqi glucoside R1
Notoginseng extracts
NOTOGINSENOSIDE R1(SH)
Notoginsenoside R1 ,98%
Notoginsenoside R1 Standard
Notoginsenoside R1，Sanchinoside R1
Notoginsenoside R1, 98%, from Panax notoginseng (Burk.)F.H.Chen
glucopyranosyloxy)-3,12-dihydroxydammar-24-en-6-yl2-O-β-D-xylopyranosyl-
(3β,6α,12β)-20-(β-D-Glucopyranosyloxy)-3,12-dihydroxydammar-24-en-6-yl 2-O-β-D-xylopyranosyl-β-D-glucopyranoside
β-D-Glucopyranoside, (3β,6α,12β)-20-(β-D-glucopyranosyloxy)-3,12-dihydroxydammar-24-en-6-yl 2-O-β-D-xylopyranosyl-
(3beta,6alpha,12beta)-20-(beta-D-Glucopyranosyloxy)-3,12-dihydroxydammar-24-en-6-yl 2-O-beta-D-Xylopyranosyl-beta-D-glucopyranoside
2-[2-[6-[[4,5-dihydroxy-6-(hydroxymethyl)-3-methyl-2-oxanyl]oxy]-3,12-dihydroxy-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-6-methylhept-5-en-2
(2S,3R,4S,5S,6R)-2-[(2S)-2-[(3S,5R,6S,8R,9R,10R,12R,13R,14R,17S)-6-[(2R,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxyoxan-2-yl]oxy-3,12-dihydroxy-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-6-methylhept-5-en-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol | [EINECS(EC#)]
208-517-5 | [Molecular Formula]
C47H80O18 | [MDL Number]
MFCD00210535 | [MOL File]
80418-24-2.mol | [Molecular Weight]
933.13 |
| Questions And Answer | Back Directory | [Description]
Notoginsenoside R1 is a ginsenoside found in Panax notoginseng that is dammarane which is substituted by hydroxy groups at the 3beta, 6alpha, 12beta and 20 pro-S positions, in which the hydroxy groups at positions 6 and 20 have been converted to the corresponding beta-D-xylopyranosyl-(1->2)-beta-D-glucopyranoside and beta-D-glucopyranoside respectively, and in which a double bond has been introduced at the 24-25 position. It is a beta-D-glucoside, a 12beta-hydroxy steroid, a 3beta-hydroxy steroid, a disaccharide derivative, a ginsenoside, a tetracyclic triterpenoid and a 3beta-hydroxy-4,4-dimethylsteroid. It derives from a hydride of a dammarane. | [Uses]
Notoginsenoside R1 is an active ingredient isolated from Panax notoginseng that induces tissue-type plasminogen activator synthesis in cultured human umbilical vein endothelial cells. | [Application]
Notoginsenoside R1 has a role as a plant metabolite, an antioxidant, a neuroprotective agent, an apoptosis inducer and a phytoestrogen. |
| Chemical Properties | Back Directory | [Melting point ]
215～217℃ | [Boiling point ]
1010.5±65.0 °C(Predicted) | [density ]
1.39±0.1 g/cm3(Predicted) | [storage temp. ]
2-8°C | [solubility ]
H2O: soluble1mg/mL, clear, colorless | [form ]
powder | [pka]
12.85±0.70(Predicted) | [color ]
white to off-white | [biological source]
Panax notoginseng (Burk.) F.H.Chen | [Water Solubility ]
H2O: 1mg/mL, clear, colorless | [InChIKey]
LLPWNQMSUYAGQI-OOSPGMBYSA-N | [LogP]
1.354 (est) |
| Hazard Information | Back Directory | [Definition]
ChEBI:Notoginsenoside R1 is a ginsenoside found in Panax notoginseng that is dammarane which is substituted by hydroxy groups at the 3beta, 6alpha, 12beta and 20 pro-S positions, in which the hydroxy groups at positions 6 and 20 have been converted to the corresponding beta-D-xylopyranosyl-(1->2)-beta-D-glucopyranoside and beta-D-glucopyranoside respectively, and in which a double bond has been introduced at the 24-25 position. It has a role as a plant metabolite, an antioxidant, a neuroprotective agent, an apoptosis inducer and a phytoestrogen. It is a beta-D-glucoside, a 12beta-hydroxy steroid, a 3beta-hydroxy steroid, a disaccharide derivative, a ginsenoside, a tetracyclic triterpenoid and a 3beta-hydroxy-4,4-dimethylsteroid. It derives from a hydride of a dammarane. | [Biological Activity]
Notoginsenoside R1 has been shown to exhibit antooxidantanti-inflammatoryantiapoptoticand immune-stimulatory properties. | [in vivo]
Notoginsenoside R1 (5 mg/kg/h; infused via the right jugular vein) increases red blood cell velocity, reduces the number of adherent leukocytes and inhibits mast cell degranulation and cytokine elevation in rats[3]. | Animal Model: | Male Sprague-Dawley (SD) rats (200-250 g)[3] | | Dosage: | 5 mg/kg/h | | Administration: | Infused 20 min before LPS infusion via the right jugular vein | | Result: | Ameliorated the LPS-induced reduction in the mesenteric venular shear rate to some extent.
Attenuated the LPS-induced adhesion of leukocytes to the venular wall.
Inhibited mast cell degranulation and cytokine elevation. |
| [storage]
Store at -20°C, protect from light |
|
|